Townsquare Capital LLC Sells 8,154 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Townsquare Capital LLC reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 76.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,546 shares of the medical research company's stock after selling 8,154 shares during the period. Townsquare Capital LLC's holdings in Charles River Laboratories International were worth $470,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in CRL. Virtu Financial LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $601,000. Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International in the third quarter worth approximately $59,000. Tidal Investments LLC increased its stake in shares of Charles River Laboratories International by 37.8% during the 3rd quarter. Tidal Investments LLC now owns 8,452 shares of the medical research company's stock worth $1,665,000 after purchasing an additional 2,319 shares during the last quarter. Lord Abbett & CO. LLC raised its holdings in shares of Charles River Laboratories International by 5.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company's stock valued at $21,413,000 after purchasing an additional 5,959 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in shares of Charles River Laboratories International by 3.6% in the 3rd quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company's stock valued at $11,917,000 after purchasing an additional 2,126 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares of the company's stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Price Performance

CRL stock traded down $1.62 during midday trading on Friday, reaching $114.14. 318,272 shares of the company's stock traded hands, compared to its average volume of 914,412. The company has a 50-day simple moving average of $147.53 and a two-hundred day simple moving average of $171.73. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The company has a market cap of $5.61 billion, a price-to-earnings ratio of 761.97, a PEG ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same period in the previous year, the business posted $2.46 earnings per share. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Mizuho cut their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. UBS Group restated a "neutral" rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. Barclays cut their price objective on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Finally, The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their target price for the company from $190.00 to $170.00 in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $182.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).